Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Supernus Pharmaceuticals Inc's Business Segments
Supernus Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 208
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 208 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product72.6%
- Qelbree37.5%
- GOCOVRI17%
- Royalty, License and Other Revenue14.1%
- Collaboration Revenue13.3%
- Trokendi XR4.6%
- ONAPGO4%
- APOKYN3.7%
- Oxtellar X R3.6%
- Manufactured Product, Other2.2%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 151 | 72.6% |
| Qelbree | $ 78 | 37.5% |
| GOCOVRI | $ 35 | 17% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
7 more categories available
Sign in to unlock the full Supernus Pharmaceuticals Inc dataset.
Description of Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals is a pharmaceutical company that specializes in the development and commercialization of treatments for central nervous system (CNS) disorders. The company was founded in 2005 and is headquartered in Rockville, Maryland, USA.
Supernus has a diverse portfolio of products in various stages of development. The company's leading products include Oxtellar XR, a treatment for partial onset seizures in adults and children, and Trokendi XR, a treatment for migraines and epilepsy. Additionally, Supernus is developing other treatments for CNS disorders, including ADHD, schizophrenia, and depression.
The company's management team has extensive experience in the pharmaceutical industry and has a track record of successful drug development and commercialization. The company has a robust intellectual property portfolio, including patents for its lead products.
Supernus has a strong partnership with the FDA and has received several FDA approvals for its products. The company also focuses on the development of drugs with improved delivery methods, including sustained-release formulations and transdermal patches.
In addition to its drug development pipeline, Supernus has a strong financial position with significant cash reserves and revenue growth. The company also has partnerships with several other pharmaceutical companies to develop and commercialize their products.
Overall, Supernus Pharmaceuticals is a well-established pharmaceutical company with a strong focus on innovation and drug development for CNS disorders. The company's diverse portfolio of products, strong management team, and financial position make it a promising player in the pharmaceutical industry.
Supernus has a diverse portfolio of products in various stages of development. The company's leading products include Oxtellar XR, a treatment for partial onset seizures in adults and children, and Trokendi XR, a treatment for migraines and epilepsy. Additionally, Supernus is developing other treatments for CNS disorders, including ADHD, schizophrenia, and depression.
The company's management team has extensive experience in the pharmaceutical industry and has a track record of successful drug development and commercialization. The company has a robust intellectual property portfolio, including patents for its lead products.
Supernus has a strong partnership with the FDA and has received several FDA approvals for its products. The company also focuses on the development of drugs with improved delivery methods, including sustained-release formulations and transdermal patches.
In addition to its drug development pipeline, Supernus has a strong financial position with significant cash reserves and revenue growth. The company also has partnerships with several other pharmaceutical companies to develop and commercialize their products.
Overall, Supernus Pharmaceuticals is a well-established pharmaceutical company with a strong focus on innovation and drug development for CNS disorders. The company's diverse portfolio of products, strong management team, and financial position make it a promising player in the pharmaceutical industry.
Supernus Pharmaceuticals Inc. is a focused pharmaceutical company dedicated to the development and commercialization of innovative treatments for central nervous system (CNS) disorders. The companys strategic approach is segmented into two primary areas: neurology and psychiatry, each offering specialized products and services to address a wide range of neurological and psychiatric conditions.
Segments
1. Neurology Segment:
This segment encompasses therapeutic options for managing epilepsy, migraines, and movement disorders. The products developed within this segment are aimed at alleviating the burden of these conditions on patients lives, improving their overall quality of life.
2. Psychiatry Segment:
This area focuses on addressing mental health issues, particularly through treatments for attention deficit hyperactivity disorder (ADHD) and schizophrenia. The companys commitment in this segment is to provide effective therapeutic solutions that can help patients manage their symptoms and lead fulfilling lives.
Products
Epilepsy
Supernus Pharmaceuticals has made significant contributions to the treatment of epilepsy with its two key antiepileptic drugs (AEDs):
- Trokendi XR: This is a once-daily, extended-release AED designed for the treatment of partial-onset seizures in addition to being indicated for the prevention of migraines in adults and adolescents aged 12 years and older. Its convenient dosing schedule helps improve patient compliance and manage seizures effectively.
- Oxtellar XR: Another extended-release AED that is indicated for the treatment of partial-onset seizures. Oxtellar XR is applicable for patients aged 6 years and older and also has an approval for the prevention of migraines in adults. The extended-release formulation aids in maintaining steady medication levels in the bloodstream, which is critical for effective seizure management.
Migraine
- Oxtellar XR: Beyond its role in epilepsy management, Oxtellar XR is also approved for the prevention of migraines, highlighting Supernuss ability to develop multifaceted treatments that can offer broader benefits to patients.
Movement Disorders
- GOCOVRI: This product is an extended-release capsule indicated for the treatment of dyskinesia in patients with Parkinsons disease who are undergoing levodopa-based therapy. GOCOVRI helps to manage the involuntary movements associated with the disease, improving the overall treatment regimen for Parkinsons patients.
ADHD
Supernus Pharmaceuticals addresses ADHD through the following products:
- Adzenys XR-ODT: This is a controlled substance, stimulant-based medication available in an orally disintegrating tablet form. Its extended-release formulation facilitates smoother symptom control throughout the day.
- Mydayis: Another CII stimulant option, Mydayis is designed for once-daily dosing with an extended-release action that covers a full 16 hours, catering to both adult and pediatric populations diagnosed with ADHD.
Psychiatric Disorders
- Aripiprazole: Used in the treatment of schizophrenia among adults, Aripiprazole is part of a broader category of atypical antipsychotics. It works by rebalancing neurotransmitters in the brain to help mitigate the symptoms associated with mental health disorders.
Services
Supernus Pharmaceuticals is committed not only to product development but also to providing comprehensive support services that enhance patient access and education:
- Patient Assistance Programs: These programs provide financial assistance to eligible patients across various income levels, ensuring that economic barriers do not prevent access to necessary medications.
- Educational Resources: The company offers a range of educational materials for patients and healthcare providers alike. Resources such as prescribing guidelines, patient support programs, and pharmacist education materials are all designed to support the effective management of neurological and psychiatric conditions.
- Continuing Education: Supernus Pharmaceuticals actively engages with healthcare professionals by offering continuing education courses and webinars focused on the management of epilepsy and other CNS disorders. This initiative aims to keep practitioners informed about the latest treatment options, patient management strategies, and developments within the field.
- Patient Referral Programs: These initiatives help streamline the process for healthcare providers to connect patients with appropriate treatments, thereby improving patient outcomes and fostering better healthcare practices.
Overall, Supernus Pharmaceuticals Inc. distinguishes itself as a leader in providing targeted pharmaceutical solutions for central nervous system disorders, reflecting a deep commitment to improving patient outcomes through innovation, support, and education. The range of products and services underlines the companys dedication to enhancing the quality of life for individuals affected by these challenging conditions.
Segments
1. Neurology Segment:
This segment encompasses therapeutic options for managing epilepsy, migraines, and movement disorders. The products developed within this segment are aimed at alleviating the burden of these conditions on patients lives, improving their overall quality of life.
2. Psychiatry Segment:
This area focuses on addressing mental health issues, particularly through treatments for attention deficit hyperactivity disorder (ADHD) and schizophrenia. The companys commitment in this segment is to provide effective therapeutic solutions that can help patients manage their symptoms and lead fulfilling lives.
Products
Epilepsy
Supernus Pharmaceuticals has made significant contributions to the treatment of epilepsy with its two key antiepileptic drugs (AEDs):
- Trokendi XR: This is a once-daily, extended-release AED designed for the treatment of partial-onset seizures in addition to being indicated for the prevention of migraines in adults and adolescents aged 12 years and older. Its convenient dosing schedule helps improve patient compliance and manage seizures effectively.
- Oxtellar XR: Another extended-release AED that is indicated for the treatment of partial-onset seizures. Oxtellar XR is applicable for patients aged 6 years and older and also has an approval for the prevention of migraines in adults. The extended-release formulation aids in maintaining steady medication levels in the bloodstream, which is critical for effective seizure management.
Migraine
- Oxtellar XR: Beyond its role in epilepsy management, Oxtellar XR is also approved for the prevention of migraines, highlighting Supernuss ability to develop multifaceted treatments that can offer broader benefits to patients.
Movement Disorders
- GOCOVRI: This product is an extended-release capsule indicated for the treatment of dyskinesia in patients with Parkinsons disease who are undergoing levodopa-based therapy. GOCOVRI helps to manage the involuntary movements associated with the disease, improving the overall treatment regimen for Parkinsons patients.
ADHD
Supernus Pharmaceuticals addresses ADHD through the following products:
- Adzenys XR-ODT: This is a controlled substance, stimulant-based medication available in an orally disintegrating tablet form. Its extended-release formulation facilitates smoother symptom control throughout the day.
- Mydayis: Another CII stimulant option, Mydayis is designed for once-daily dosing with an extended-release action that covers a full 16 hours, catering to both adult and pediatric populations diagnosed with ADHD.
Psychiatric Disorders
- Aripiprazole: Used in the treatment of schizophrenia among adults, Aripiprazole is part of a broader category of atypical antipsychotics. It works by rebalancing neurotransmitters in the brain to help mitigate the symptoms associated with mental health disorders.
Services
Supernus Pharmaceuticals is committed not only to product development but also to providing comprehensive support services that enhance patient access and education:
- Patient Assistance Programs: These programs provide financial assistance to eligible patients across various income levels, ensuring that economic barriers do not prevent access to necessary medications.
- Educational Resources: The company offers a range of educational materials for patients and healthcare providers alike. Resources such as prescribing guidelines, patient support programs, and pharmacist education materials are all designed to support the effective management of neurological and psychiatric conditions.
- Continuing Education: Supernus Pharmaceuticals actively engages with healthcare professionals by offering continuing education courses and webinars focused on the management of epilepsy and other CNS disorders. This initiative aims to keep practitioners informed about the latest treatment options, patient management strategies, and developments within the field.
- Patient Referral Programs: These initiatives help streamline the process for healthcare providers to connect patients with appropriate treatments, thereby improving patient outcomes and fostering better healthcare practices.
Overall, Supernus Pharmaceuticals Inc. distinguishes itself as a leader in providing targeted pharmaceutical solutions for central nervous system disorders, reflecting a deep commitment to improving patient outcomes through innovation, support, and education. The range of products and services underlines the companys dedication to enhancing the quality of life for individuals affected by these challenging conditions.